Very recently, a phase III study of anti-PD-L1 (atezolizumab) and nab-paclitaxel in advanced triple-negative BC showed that, among patients with PD-L1 positive tumors, progression-free survival was statistically significantly longer in patients treated with the combination of atezolizumab + nab-paclitaxel compared with those treated with a placebo + nab-paclitaxel (17). Here, CD274 is linked to breast cancer.